Diagnostics Products, Bard, and Abbott beware,
NMP is going after your market share. The monk speaks in technical
tongue, and the market listens. You do not need to pat yourself on
the back, leave it up to me. Your unrealistic and ridiculous price
forcasts are indeed acheiveable and realistic. If this co. got to
18 on hope alone, we will surely see the levels you predict. Retesting
the 200 dma is what sounds unrealistic to me.
When I spoke to PR man Ronald Trahan, he led me to beleive the ppo
would indeed come. Who cares, not I. With the potential of this tech.,
and the experience and knowledge of our resident man of levitation,
we will be handsomely rewarded in the months ahead.
Nonevent 2nd qtr #'s will be out soon, but hopefully the co. will
provide info on the progress of our hired guns at Urocor,
as well as the European units, in the interim. With the prospects of
colorectal, prostate, cervical, breast, and lung cancer markers in the
works, we have a long way to go...Long term, a bumpy ride will not
matter. Patrick, my thirst for your views will never be quenched, keep
it coming, and watch out for that ceiling while meditating...
best returns |
